Abstract：Objective: To investigate the relationship between human papillomavirus(HPV) E6 protein and chloride voltagegated channel 5(CLCN5), and to explore the effect of CLCN5 on the migration of cervical cancer cells. Methods: RNA interference technique was used to knock down the E6 gene of HPV, realtime quantitative PCR(RTqPCR) and Western blotting were used to detect the expression of CLCN5 mRNA and protein in cervical cancer HeLa cells, after knockingdown HPV E6 gene. The CLCN5 gene fragment was amplified by PCR and then cloned into pCDNA3.1 to construct the recombinant expression plasmid pCDNA3.1CLCN5. The control vector pCDNA3.1 and the target plasmid pCDNA3.1CLCN5 were transfected into cervical cancer HeLa cells respectively, after which Western blotting was used to detect the expression of CLCN5. Transwell migration assay was used to detect the effect of overexpression of CLCN5 on the migration of cervical cancer HeLa cells. Meanwhile, negative control and CLCN5 small interfering RNA were transfected into cervical cancer HeLa cells.Transwell migration assay was used to detect the effect of knockdown of CLCN5 on the migration of cervical cancer HeLa cells. Results: The results of RTqPCR and Western blotting showed that both the mRNA and protein level of CLCN5 was significantly decreased after HPV E6 was knocked down. The result of transwell migration showed that overexpression of CLCN5 could promote cell migration, while knockdown of CLCN5 could inhibit cell migration. Conclusion: HPV E6 protein promotes the migration of cervical cancer cells by upregulating the expression of CLCN5.
收稿日期: 2018-01-23
通讯作者:
卢春（通讯作者），教授，博士生导师，E-mail:clu@njmu.edu.cn
作者简介: 赵凯旋（1990—），女，硕士研究生
引用本文:
赵凯旋， 徐静云， 卢春. 人乳头瘤病毒E6蛋白通过上调氯离子蛋白通道5的表达促进宫颈癌细胞迁移[J]. 江苏大学学报:医学版, 2018, 28(02): 135-139.
ZHAO Kaixuan, X Jingyun, LU Chun. Human papillomavirus E6 protein promotes the migration of cervical cancer cells by up-regulating the expression of chloride voltage-gated channel 5. Journal of Jiangsu University(Medicine Edition), 2018, 28(02): 135-139.
［1］Burd EM. Human papillomavirus and cervical cancer\[J\]. Clin Microbiol Rev, 2003, 16(1): 1-17.［2］Goon PK, Stanley MA, Ebmeyer J, et al. HPV & head and neck cancer: a descriptive update\[J\]. Head Neck Oncol, 2009, 1:36.［3］zur Hausen H. Papillomaviruses in the causation of human cancersa brief historical account\[J\]. Virology, 2009, 384（2）:260-265.［4］Tilborghs S, Corthouts J, Verhoeven Y, et al. The role of nuclear factorκ B signaling in human cervical cancer\[J\]. Crit Rev Oncol Hematol, 2017, 120:141-150.［5］Zheng ZM, Tao M, Yamanegi K, et al. Splicing of a capproximal human papillomavirus 16 E6E7 intron promotes E7 expression, but can be restrained by distance of the intron from its RNA 5′ cap\[J\]. J Mol Biol, 2004, 337（5）:1091-1108.［6］Tang S, Tao M, McCoy JP Jr, et al. The E7 oncoprotein is translated from spliced E6*I transcripts in highrisk human papillomavirus type 16 or type 18positive cervical cancer cell lines via translation reinitiation\[J\]. J Virol, 2006, 89(9):4249-4263.［7］Magaldi TG, Almstead LL, Bellone S, et al. Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation\[J\]. Virology, 2012, 422(1):114-124.［8］McFarlane M, MacDonald AI, Stevenson A, et al. Human papillomavirus 16 oncoprotein expression is controlled by the cellular splicing factor SRSF2 (SC35)\[J\]. J Virol, 2015, 89(10):5276-5287.［9］Ganti K, Broniarczyk J, Manoubi W, et al. The human papillomavirus E6 PDZ binding motif: from life cycle to malignancy\[J\]. Viruses, 2015, 7(7):3530-3551.［10］Picollo A, Malvezzi M, Accardi A. Proton block of the CLC5 Cl-/H+ exchanger\[J\]. J Gen Physiol, 2010, 135(6):653-659.［11］Satoh N, Suzuki M, Nakamura M, et al. Functional coupling of VATPase and CLC5\[J\]. World J Nephrol, 2017, 6(1):14-20.［12］Carr G, Simmons N, Sayer J. A role for CBS domain 2 in trafficking of chloride channel CLC5\[J\]. Biochem Biophys Res Commum, 2003, 310(2):600-605.［13］Tang X, Brown MR, Cogal AG, et al. Functional and transport analyses of CLCN5 genetic changes identified in Dent disease patients\[J\]. Physiol Rep, 2016, 4(8):e12776.［14］Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012\[J\]. CA Cancer J Clin, 2012, 65(2):87-108.［15］Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation\[J\]. Nat Rev Cancer, 2010, 10(8):550-560.［16］McLaughlinDrubin ME, Münger K. Oncogenic activities of human papillomaviruses\[J\]. Virus Res, 2009, 143(2):195-208.［17］Hu D, Zhou J, Wang F, et al. HPV16 E6/E7 promotes cell migration and invasion in cervical cancer via regulating cadherin switch in vitro and in vivo\[J\]. Arch Gynecol Obste, 2015, 292(6):1345-1354.［18］Ram BM, Dolpady J, Kulkarni R, et al. Human papillomavirus (HPV) oncoprotein E6 facilitates calcineurinnuclear factor for activated T cells 2 (NFAT2) signaling to promote cellular proliferation in cervical cell carcinoma\[J\]. Exp Cell Res, 2018, 362(1):132-141.［19］Chiang C, Pauli EK, Biryukov J, et al. The human papillomavirus E6 oncoprotein targets USP15 and TRIM25 to suppress RIGImediated innate immune signaling\[J\]. J Virol, 2018,92(6):e01737.［20］Iuliano M, Mangino G, Chiantore MV, et al. Human papillomavirus E6 and E7 oncoproteins affect the cell microenvironment by classical secretion and extracellular vesicles delivery of inflammatory mediators\[J\]. Cytokine, 2017.Doi:10.1016/j.cyto.2017.11.003.
2018, Vol. 28 
